A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707)
Phase 1/2
130
about 3.7 years
18–89
6 sites in CO, FL, MA +2
What this study is about
This trial is testing a treatment called EIK1004 (IMP1707) in people with advanced solid tumors. The goal is to see if the treatment is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take EIK1004-001 (IMP1707-001)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants who experience a Dose-Limiting Toxicity (DLT), Number of participants with adverse events, treatment emergent adverse events or serious adverse events
Secondary: Objective Response (OR), Pharmacokinetic parameters of EIK1004 (IMP1707)